Divya Dahiya

Divya Dahiya

Auto-generated profile, based on publicly available information

Divya Dahiya

Department of General Surgery, PGIMER, Chandigarh, 160012, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2025 in Turkish Journal of Surgery
Verified
Journal Article
Open access
PDF file
MRManish Rohilla
Manish Rohilla
CTCHERRING TANDUP
CHERRING TANDUP
DDDivya Dahiya
Divya Dahiya
ABArunanshu Behera
Arunanshu Behera
SBSanjay Kumar Bhadada
Sanjay Kumar Bhadada
SPSree Vani Paladugu
Sree Vani Paladugu
Evaluation of quality of life in primary hyperparathyroidism patients: Pre- and post-parathyroidectomy outcomes in an Indian cohort - Turkish Journal of Surgery

3 June 2026 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PAPiyush Aggarwal
Piyush Aggarwal
ASAshwani Sood
Ashwani Sood
DKDivya Khosla
Divya Khosla
RKRAKESH KAPOOR
RAKESH KAPOOR
GPGaurav Prakash
Gaurav Prakash
BMBhagwant Rai Mittal
Bhagwant Rai Mittal

26 August 2026 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
SBSohini Banerjee
Sohini Banerjee
USUma Nahar Saikia
Uma Nahar Saikia
ASApurva Sood
Apurva Sood
PAPiyush Aggarwal
Piyush Aggarwal
SMSoham Mukherjee
Soham Mukherjee
JBJaimanti Bakshi
Jaimanti Bakshi

15 December 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PKPoonam Kumari
Poonam Kumari
SBSanjay Kumar Bhadada
Sanjay Kumar Bhadada
AAAshutosh Kumar Arya
Ashutosh Kumar Arya
JKJYOTDEEP KAUR
JYOTDEEP KAUR
NSNaresh Sachdeva
Naresh Sachdeva
SRSudhaker D Rao
Sudhaker D Rao
Introduction: Primary hyperparathyroidism (PHPT) is a systemic endocrine disorder characterized by elevated PTH levels and hypercalcemia. Gene-specific epigenetic modifications like histone methylation play a pivotal role in PHPT by altering expression of parathyroid-specific genes. However, global histone modifications in parathyroid tumors and their implications for tumor behavior remain underexplored. Experimental Design: We performed comparative histone modification profiling in blood and tissue samples from sporadic parathyroid adenomas (PA; n = 30), atypical parathyroid tumors (APT; n = 05), and parathyroid carcinomas (PC; n = 05) along with controls using histone H3 multiplex immunoassay. Significantly dysregulated modifications were validated by Western blotting (WB), and expression data was correlated with clinicopathological features. We performed pathway enrichment analysis to elucidate molecular pathways potentially linked to histone H3 modifications in parathyroid tumorigenesis. Results: We observed dynamic alterations in histone H3 modifications of lysine (K) residues across parathyroid tumor phenotypes in blood and tissue samples. A reduction in H3K4 and H3K36 trimethylation (130%) compared to controls was observed. WB confirmed lower H3K4me3 (0.5 ± 0.4 vs 4.4 ± 0.7, P = .02; 0.4 ± 0.2 vs 4.4 ± 0.7, P = .004) and H3K36me3 (0.4 ± 0.2 vs 1.0 ± 0.3, P = .03; 0.2 ± 0.1 vs 1.0 ± 0.3, P = .02) in APT and PC than controls and higher H3K27me3 expression in PA (2.9 ± 1.2 vs 1.1 ± 0.21, P = .04), APT (4.2 ± 2.9 vs 1.1 ± 0.21, P = .007), and PC (6.9 ± 3.1 vs 1.1 ± 0.21, P = .0002) relative to controls. Pathway enrichment analysis identified molecular pathways, including calcium signaling, Wnt, and Hippo signaling, associated with histone H3 modifications. Conclusion: Increased expression of repressive H3K27me3 in blood and tissue samples, while decreased H3K4me3 and H3K36me3, suggest a shift toward transcriptional repression. Identifying their functional mechanisms may facilitate the discovery of novel insights for therapeutic targeting in parathyroid tumors.